Jern-jon Kuo, MD in Cheswick, PA - Otolaryngology

Jern-jon Kuo, MD is a Otolaryngology physician based in Cheswick, Pennsylvania. Jern-jon Kuo is licensed to practice in West Virginia (license number 11083) and his current practice location is 503 Sandra Ln, Cheswick, Pennsylvania. He can be reached at his office (for appointments etc.) via phone at (412) 767-5022.

NPI number for Jern-jon Kuo is 1154557759 and his current mailing address is 503 Sandra Ln, Cheswick, Pennsylvania. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1154557759.

Contact Information

	Jern-jon Kuo, MD
	503 Sandra Ln, Cheswick, PA 15024-4017
	(412) 767-5022
	Not Available

Physician's Profile

Full Name	Jern-jon Kuo
Gender	Male
Speciality	Otolaryngology
Location	503 Sandra Ln, Cheswick, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1154557759
Provider Enumeration Date: 06/09/2009
Last Update Date: 06/09/2009

Medical Identifiers

Medical identifiers for Jern-jon Kuo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1154557759	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Y00000X	Otolaryngology	11083 (West Virginia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jern-jon Kuo is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Jern-jon Kuo, MD 503 Sandra Ln, Cheswick, PA 15024-4017 Ph: () -	Jern-jon Kuo, MD 503 Sandra Ln, Cheswick, PA 15024-4017 Ph: (412) 767-5022

News Archive

New breath test to tailor the dosage of drugs administered to epileptic patients

Epilepsy affects some 50 million people worldwide and pharmaceutical treatment of the disease is a tightrope walk, as the dose must be tailored precisely to the individual patient: "Slightly too little and it isn't effective. Slightly too much and it becomes toxic," explains Professor Pablo Sinues.

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

Caliper Life Sciences, Inc., today reported results for its second quarter ended June 30, 2010. Second quarter GAAP revenue decreased 10% to $29.0 million from $32.1 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 4% on a reported basis and 6% on an organic basis (which assumes constant currency).

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates.

Researchers investigate preferences for participation in decision-making process among AMI patients

In a research letter, Harlan M. Krumholz, M.D., S.M., from Yale University School of Medicine and colleagues, "sought to investigate preferences for participation in the decision-making process among individuals hospitalized with an acute myocardial infarction ([AMI] or heart attack)."

Jern-jon Kuo, MD - Otolaryngology in Cheswick, PA